Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials

INTRODUCTION: The Janus kinase (JAK) inhibitor therapeutic class has shown significant clinical benefit in the treatment of rheumatoid arthritis (RA). We sought to gain insight into the mode of action and immunological effects of filgotinib, a JAK1 selective inhibitor, in active RA by analyzing secr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tarrant, Jacqueline M., Galien, René, Li, Wanying, Goyal, Lovely, Pan, Yang, Hawtin, Rachael, Zhang, Wangshu, Van der Aa, Annegret, Taylor, Peter C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021851/
https://www.ncbi.nlm.nih.gov/pubmed/31912462
http://dx.doi.org/10.1007/s40744-019-00192-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021851/
https://www.ncbi.nlm.nih.gov/pubmed/31912462
http://dx.doi.org/10.1007/s40744-019-00192-5

Ejemplares similares